SunTrust analyst Edward Nash views this morning's rally in shares of Sarepta Therapeutics (SRPT) after the FDA failed to meet its eteplirsen goal review date as unwarranted. The FDA was also unable to complete the review of BioMarin's (BMRN) Duchenne muscular dystrophy treatment by the action date date, but eventually issued a Complete Response Letter, Nash points out to investors. He believes today's development should not be viewed as indicative for a favorable decision by the Agency. Nash continues to expect the FDA to reject eteplirsen based on the briefing documents. Shares of Sarepta are up 18%, or $3.30, to $21.74 in pre-market trading. The stock is off its highs, however.